Sparrow ramps up monoclonal antibody treatments to protect community against COVID

sparrow hospital
Posted at 8:45 AM, Apr 19, 2021
and last updated 2021-04-19 08:45:52-04

LANSING, Mich. — Sparrow has greatly expanded its delivery of monoclonal antibody treatment to the community, shifting from a few dozen treatments a week to as many as 360 infusions weekly to combat the COVID-19 virus.

The move coincides with Gov. Gretchen Whitmer’s call for increased antibody infusions and the FDA’s emergency use authorization for use of monoclonal antibodies to treat high-risk mild to moderate COVID-19 patients who meet very specific criteria. Monoclonal treatment has been shown to reduce the risk of hospitalization and death by 87 percent.

As Sparrow emphasizes vaccinations as well as testing for the COVID virus, monoclonal treatment is one of the most important mitigation strategies for use against COVID. Sparrow’s goal is to aggressively treat those who qualify for the treatment.

Monoclonal treatment is an outpatient therapy conducted intravenously at Sparrow’s Specialty Infusion Clinic at the Sparrow St. Lawrence Campus, 1210 W. Saginaw, Lansing; at Sparrow Carson Hospital; and Sparrow Ionia Hospital. The therapy begins April 27 at Sparrow Clinton and Sparrow Eaton. Patients must check with their doctor to see if they are eligible and receive a physician’s order in order to receive the treatment.

Sparrow doubled its infusion treatments last week and now has the ability to deliver a maximum of 60 a day across the health system. Sparrow is also currently working to develop a process to deliver and infuse those patients who are homebound, unable to access transportation and meet the eligibility criteria.

For more information, go to

Check out other Health related articles in our Yes to Healthy Living section of our website.

Stay in touch with us anytime, anywhere.

Download our free apps


Sign up for newsletters emailed to your inbox.

Select from these options: Breaking News, Severe Weather, School Closings, Daily Headlines and Daily Forecasts.

Follow us on Twitter

Like us on Facebook